Seroatlas · Human Serome Atlas

BRD7

Bromodomain-containing protein 7

Also known as: BP75, BRD7_HUMAN, CELTIX1, SMARCI1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9NPI1
Gene
BRD7
Ensembl
ENSG00000166164
Chromosome
16
Canonical length
651 aa
Protein class
Predicted intracellular proteins
Subcellular location
Nucleoplasm,Cytosol

OverviewNCBI Gene

This gene encodes a protein which is a member of the bromodomain-containing protein family. The product of this gene has been identified as a component of one form of the SWI/SNF chromatin remodeling complex, and as a protein which interacts with p53 and is required for p53-dependent oncogene-induced senescence which prevents tumor growth. Pseudogenes have been described on chromosomes 2, 3, 6, 13 and 14. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2010]

Canonical amino-acid sequenceUniProt

651 residues, UniProt reviewed canonical sequence.

>Q9NPI1|BRD7
     1  MGKKHKKHKS DKHLYEEYVE KPLKLVLKVG GNEVTELSTG SSGHDSSLFE DKNDHDKHKD
    61  RKRKKRKKGE KQIPGEEKGR KRRRVKEDKK KRDRDRVENE AEKDLQCHAP VRLDLPPEKP
   121  LTSSLAKQEE VEQTPLQEAL NQLMRQLQRK DPSAFFSFPV TDFIAPGYSM IIKHPMDFST
   181  MKEKIKNNDY QSIEELKDNF KLMCTNAMIY NKPETIYYKA AKKLLHSGMK ILSQERIQSL
   241  KQSIDFMADL QKTRKQKDGT DTSQSGEDGG CWQREREDSG DAEAHAFKSP SKENKKKDKD
   301  MLEDKFKSNN LEREQEQLDR IVKESGGKLT RRLVNSQCEF ERRKPDGTTT LGLLHPVDPI
   361  VGEPGYCPVR LGMTTGRLQS GVNTLQGFKE DKRNKVTPVL YLNYGPYSSY APHYDSTFAN
   421  ISKDDSDLIY STYGEDSDLP SDFSIHEFLA TCQDYPYVMA DSLLDVLTKG GHSRTLQEME
   481  MSLPEDEGHT RTLDTAKEME ITEVEPPGRL DSSTQDRLIA LKAVTNFGVP VEVFDSEEAE
   541  IFQKKLDETT RLLRELQEAQ NERLSTRPPP NMICLLGPSY REMHLAEQVT NNLKELAQQV
   601  TPGDIVSTYG VRKAMGISIP SPVMENNFVD LTEDTEEPKK TDVAECGPGG S

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against BRD7 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.55
Highest tissue expression
62 nTPM

Expression across tissuesHPA

Tissue

  • bone marrow: 62 nTPM
  • spinal cord: 57 nTPM
  • midbrain: 54 nTPM
  • skeletal muscle: 54 nTPM
  • testis: 53 nTPM
  • thymus: 53 nTPM

Single-cell type

  • early primary spermatocytes: 209 nCPM
  • differentiating spermatogonia: 199 nCPM
  • erythrocyte progenitors: 166 nCPM
  • undifferentiated spermatogonia: 160 nCPM
  • ocular epithelial cells: 157 nCPM
  • esophageal apical cells: 154 nCPM

Immune cell

  • NK-cell: 9.9 nTPM
  • naive CD8 T-cell: 8.7 nTPM
  • plasmacytoid DC: 8.5 nTPM
  • eosinophil: 7.6 nTPM
  • naive CD4 T-cell: 7.1 nTPM
  • T-reg: 6.9 nTPM

Brain region

  • white matter: 52 nTPM
  • medulla oblongata: 49 nTPM
  • basal ganglia: 48 nTPM
  • hypothalamus: 48 nTPM
  • cerebellum: 45 nTPM
  • midbrain: 44 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about BRD7.

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 116 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Granular cell cancer

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.26
gnomAD pLI
1
gnomAD missense Z
0.49
DepMap mean gene effect
-0.3
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of BRD7 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads BRD7 as an antibody target. Whether an autoantibody or antibody against BRD7 could matter depends on whether native BRD7 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

BRD7 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label BRD7 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/BRD7. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...